Command Palette

Search for a command to run...

novelix-pharmaceuticals

39.2-2.00%
Market Cap
₹57.92 Cr
Stock P/E
-36.02
ROCE
-28.57%
ROE
-29.63%
Book Value
₹0.00

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Public
Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Laggard

Novelix Pharmaceuticals Ltd. significantly underperforms compared to its peers across all key metrics. With negative growth, high valuation ratios, and low profitability, it presents a concerning picture for investors. In contrast, Adani Enterprises and Redington stand out as strong performers in terms of growth and profitability.

Key Points
  • Novelix Pharmaceuticals shows negative revenue growth and EPS, indicating poor performance.
  • Adani Enterprises and Redington show strong revenue growth and profitability metrics.
  • High PE ratios across the board suggest overvaluation, especially for Novelix.
  • Companies like MMTC and Honasa are financially weak with negative EPS and cash flow concerns.
Top Performers
Adani Enterprises Ltd.

Strong revenue growth (1.53% YoY), low PE of 43.53, and solid ROE of 9.48%

Redington Ltd.

Highest revenue growth (12.56% YoY), solid profitability with ROE of 17.12% and low PE of 13.20

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.